EMERYVILLE, Calif.—NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reported financial results for the three and 12 months ended December 31, 2023. Total sales, net for the fourth quarter of 2023 were $3.7 million, an increase of 2 percent from $3.6 million for the prior-year period, with the increase due to higher Avenova and wound care product sales. Net product revenue for the fourth quarter of 2023 included $2.8 million from the eyecare and wound care segment, and $0.9 million from the skin care segment. Total sales, net for 2023 were $14.7 million, an increase of 2 percent from $14.4 million for 2022, and included $11.2 million from the eyecare and wound care segment, and $3.6 million from the skin care segment. Read More